Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
Relief Therapeutics (RLFTF) and NeuroRx announce that more than 175 patients with Critical COVID-19 and Respiratory Failure have now been entered into an Expanded Access Protocol ((EAP)) with RLF-100 in the U.S. All patients had severe comorbidities (such as organ transplant, recent heart att...
GENEVA, SWITZERLAND / ACCESSWIRE / November 23, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today g...
Relief Therapeutics (RLFTF) appoints Syneos Health (SYNH), a global clinical research organization, to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications.Relief has also selected AMRI, a global contract development and manufac...
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure - Observations of rapid recovery noted on chest x-ray and no drug-related Serious Adverse Events reported PR Newswire ...
Relief Therapeutics (RLFTF) with its partner NeuroRx, announce that 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100 (aviptadil) for treating respiratory failure in patients with critical COVID-19.So far, no drug-related serious ...
NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020 PR Newswire RADNOR, Pa. and GENEVA, Nov. 5, 2020 RADNOR, Pa. and GENEVA , Nov. 5, ...
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today an...
Relief Therapeutics (RLFTF) and NeuroRx announce topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to ICU with critical COVID-19 and respiratory failure were treated with RLF-100 (Aviptadil) compared to 24 control patients treate...
NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19 - RLF-100™ therapy associated with a 9-fold increased pr...
Relief Therapeutics (RLFTF) has appointed Jack Weinstein as Chief Financial Officer ((CFO)) and Treasurer, effective immediately.Mr. Weinstein brings over 40 years of wide-ranging expertise. Before joining Relief, he served as Managing Director and Head of Healthcare Investment Banking at Ava...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
Mondobiotech Holding AG Basel Website:
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, ann...
GENEVA, SWITZARLAND / ACCESSWIRE / May 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the Annual General Mee...
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...